You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥(01099.HK)附屬與默沙東簽訂抗新冠口服藥物內地經銷協議
國藥控股(01099.HK)公布,控股股東國藥集團已於去年9月與默沙東簽署合作框架協議,獲授默沙東與Ridgeback合作研發的抗新冠病毒口服藥物莫諾拉韋膠囊(商品名:利卓瑞)在中國境內的經銷權和獨家進口權。去年11月,公司附屬國藥控股分銷中心與默沙東簽署經銷協議,在協議期內負責莫諾拉韋在中國的進口和經銷。產品的最終使用及銷售情況受疫情等因素影響,存在較大不確定性。 莫諾拉韋是全球首款獲批的口服抗新冠病毒藥物,去年12月30日,國家藥監局宣布莫諾拉韋已獲得應急附條件批准,用於治療成人伴有進展為重症高風險因素的輕至中度新冠病毒感染(COVID-19)患者。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account